Member Info for Krone

Remarkable pre-clinical promise.....
'Novel Immunotherapy Combinations and Targets'
Beyond PD-(L)1 and CTLA-4, a number of other combinatorial approaches to augment the efficacy of immune checkpoint blockade are under active exploration. One approach showing remarkable preclinical promise are combinations of agents targeting DNA damage repair pathways and cell cycle regulators, including PARP1 and CHK1/2.10

New approaches to small cell lung cancer therapy : from the laboratory to the clinic. https://www.jto.org/article/S1556-0864(20)30056-3/fulltext
Not sure if this has previously been posted.
Note Lauren Byers reports receiving personal fees from Sierra. Also SRA737 gets is referenced albeit obliquely.

https://endpts.com/a-name-emerges-out-of-the-gilead-ma-rumor-mill-and-its-a-cancer-biotech/

System glitch or update in progress...

Fax - Forty Seven is a US Inc Co - based at Menlo Park, just round the corner from SRI...

RMM - yes, too many sleepless nights for too long!!

Potnak - are they not awash with cash after the recent fundraise. Just don’t like the cut of Glover’s jib!

‘ We’ll discuss 2019 year end progress and Sierra’s 2020 outlook.’

http://investor.sierraoncology.com/2020-02-26-Sierra-Oncology-to-Hold-Year-End-2019-2020-Outlook-Analyst-Investor-Call

http://investor.sierraoncology.com/2020-02-25-Sierra-Oncology-to-Present-at-the-Cowen-40th-Annual-Health-Care-Conference

Join our CEO Dr. Nick Glover as he discusses the #MOMENTUMClinicalTrial for patients with #myelofibrosis at the Cowen 40th Annual Health Care Conference. If you won’t be in Boston, tune into the LIVE audio webcast! For more information ow.ly/cInV30qkxzp

Are we expecting Sierra results to include a substantive update on SRA737 trials and progress or otherwise regarding non-dilutive funding exercise. If substantive trial update presumably CRT and thereby Sareum will have been appraised of the trial results and will be in a position to issue an RNS which impacts positively on sp.

Hi RMM, thanks for the reassurance...like some others I am more than a little jittery at the moment...although expect it will come good eventually.

It appears that Tim will be presenting at Biotrinity 28/29 April. Surely we are much further down the road that this!!!!
"BioLaunchPad is the company showcase platform of BioTrinity, where R&D companies, TTO's and anyone else wishing to share their commercial proposition can do so via our packed schedule of back to back 5-minute presentations."

Although Sareum bod are looking for significantly bigger deal size!!!
https://www.fiercebiotech.com/biotech/gsk-pays-50m-for-two-solid-tumor-cell-therapies-from-immatics?

Mike Quigley was most recently head of Bristol-Myers Squibb's (NYSE: BMY) tumor microenvironment modulation thematic research center — leading a team essentially trying to amp up the ability of so-called cancer immunotherapy drugs to work in more patients with more types of cancer — and will be Gilead's senior vice president of research biology.

Thoth2 - well spotted! https://www.bizjournals.com/sanfrancisco/news/2020/02/19/gilead-bristol-myers-squibb-mike-quigley-gild-bmy.amp.html

Good plain English article looking at the autoimmune opportunities for Tyk2 inhibitors. The @Sareumplc compounds which are advancing towards the clinic have potential best in class properties.
Discovery of gene associated with 20 autoimmune diseases leads to promising drug trials

Melissa Grant-Peters, Calliope Athina Dendrou, University of Oxford

February 19, 2020 11.26am GMT

Cold fish pie - well said!

We keep coming back to the perennial problem with Sareum of pi** poor communications. We had the teleconference and AGM which lifted spirits momentarily and then nothing not even a Proactiveinvestors interview. The EGM question will be table again sooner rather than later. My fear is that a further raise in the near future will crash the sp even further in the absence of positive and substantive news!